美国骨髓瘤免疫治疗联盟关于 Teclistamab 治疗复发/难治性多发性骨髓瘤的真实世界经验

UNLABELLED: Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma.

We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1. 4% grade ≥3) and immune effector cell-associated neurotoxicity syndrome in 11% (2. 2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%.

Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10. 1 months of median follow-up, the estimated median progression-free survival (PFS) was 5. 8 months and 12-month overall survival was 61%.

Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. SIGNIFICANCE: T cell-engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers.

This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al. , p. 542.